Published on 25 April 2014
World Malaria Day 2014: ‘Invest in the Future. Defeat Malaria’
On the occasion of World Malaria Day 2014, the World Health Organization calls on all to continue investing in the future and defeat malaria which still kills an estimated 627 000 people every year, mainly children under 5 years of age in sub-Saharan Africa. Global efforts to control and eliminate malaria have saved an estimated 3.3 million lives, reducing malaria mortality rates by 42% globally and 49% in Africa. Increased political commitment and funding have helped to reduce malaria incidence by 25% globally, and 31% in Africa. However, there is an urgent need to continued investments in malaria control and research in order to secure these gains and make further progress. EDCTP fully supports these goals.
The second EDCTP programme (2014-2023)
The strategy for the second EDCTP programme as regards malaria will prioritise investments in research aligned with the threefold Global Malaria Action Plan. This plan focusses on control, elimination and research. In 2013, EDCTP organised a Stakeholder meeting on malaria in Vienna, Austria on 19-20 September 2013. It was co-hosted by the Austrian Ministry of Science and Research and the Medical University of Vienna and attended by 63 invited participants, including researchers from academia, representatives of product development partnerships and the pharmaceutical industry, policy makers, funding agencies and other likeminded organisations.
(A full report is available on the EDCTP website together with other materials pertaining to the meeting.)
Overview of EDCTP investments in malaria research
EDCTP malaria grants portfolio by intervention/topic
As resistance of malaria parasites to conventional antimalarial drugs is emerging, it is important to support development of new drugs and combination regimens. EDCTP provided € 19.53 million to support 19 projects on malaria treatment, which include studies of artemisinin-based combination therapies (ACTs) and non-ACTs. The studies aimed to establish therapies that are safe and highly effective in real life situations.
Moreover, current studies aim to address the needs of patient groups that need special attention such as infants, malnourished children, HIV/AIDS co-infected individuals and pregnant women. EDCTP funds three studies with a grant value of € 11 million focusing on malaria in this population which have been implemented by the Malaria in Pregnancy Consortium.
An effective and highly efficacious malaria vaccine is required to help reduce the burden of malaria in endemic countries. Since 2003, EDCTP has spent € 17.35 million to support six projects that include clinical trials of vaccines and projects that have a focus on immunological responses and capacity building for vaccine trials. Among these projects are the studies of the Malaria Vectored Vaccine Consortium (MVVC).
WANECAM: integrated approach to malaria treatment in West Africa
The overall objective of the project is the development of a sub-regional network equipped with state of the art clinical trial sites, laboratories, research teams and well characterized populations ready to undertake Phase I–IV development of new drugs. The goals of malaria control may never be achieved without strong involvement of African scientists who are directly affected by this terrible disease in their daily lives.
Professor Abdoulaye Djimdé and
The primary objective of the clinical study is to compare the incidence rate of uncomplicated malaria episodes in children and adults treated with repeated ACTs over a period of 2 years. In this 3-arm study pyronaridine-artesunate (PA) and dihydroartemisinin-piperaquine (DHA-PQP) will be compared to either artesunate-amodiaquine (ASAQ) or artemether-lumefantrine (AL) (depending on the site location). PA and DHA-PQP will not be formally compared. Clinical trials are well underway in all three countries with seven study sites actively recruiting patients. Major infrastructure upgrades were conducted in all study sites. New state of the art laboratory equipment was provided to each of the seven trial sites. Short term training in various aspects of the study including ethics, good clinical and laboratory practices, molecular biology, data management, financial management were accomplished. The Guinea observational study was completed and data cleaning and analysis is underway. The project is expected to be completed in September 2014.
Transport of WANECAM